Genscript Biotech Stock Value
Genscript Biotech Company Info
EPS Growth 5Y
20,35%
Market Cap
HK$27,85 B
Long-Term Debt
HK$4,43 B
Annual earnings
N/A
Dividend
HK$0,00
Dividend Yield
0,00%
Founded
2002
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
HK$17,52
36.77%
Last Update: 04/10/2026
Analysts: 8
Highest Price Target HK$24,69
Average Price Target HK$17,52
Lowest Price Target HK$15,50
In the last five quarters, Genscript Biotech’s Price Target has fallen from HK$27,34 to HK$21,42 - a -21,65% decrease. Eight analysts predict that Genscript Biotech’s share price will increase in the coming year, reaching HK$17,52. This would represent an increase of 36,77%.
Top growth stocks in the health care sector (5Y.)
What does Genscript Biotech do?
Genscript Biotech Corporation (Genscript), an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. The company provides a wide range of life-science research and application services, including biologics development, synthetic biology, and cell therapy.
Business Segments
The company operates through five d...
Genscript Biotech Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Revenue distribution by sectors:**
- Biotechnology services: approx. 60%
- Cell and gene therapy: approx. 25%
- Biopharmaceutical products: approx. 15%
**TOP 3 markets and their percentage shares:**
- USA: approx. 40%
- China: approx. 35%
- Europe: approx. 15%
Genscript Biotech Corporation gener...
At which locations are the company’s products manufactured?
**Production Sites:**
- **Nanjing, China**
- **Piscataway, New Jersey, USA**
Genscript Biotech Corporation operates its main production facilities in Nanjing, China, where a large portion of biotechnological products is manufactured. Additionally, the company has a significant production plant in P...
What strategy does Genscript Biotech pursue for future growth?
**Revenue Growth:** 18.5% (2024)
**R&D Investments:** 20% of revenue (2024)
Genscript Biotech Corporation pursues a growth strategy that is heavily focused on research and development (R&D). The company invests approximately 20% of its revenue in R&D to strengthen its position in the bi...
Which raw materials are imported and from which countries?
**Main raw materials:** Oligonucleotides, peptides, enzymes, antibodies
**Countries of origin:**
- **USA:** Main supplier of specialized biotechnology raw materials such as enzymes and antibodies.
- **Germany:** Leading in the provision of high-quality peptides and oligonucleotides.
- **China:** Lo...
How strong is the company’s competitive advantage?
**Market share in the biotech industry:** 5% (2024, estimate)
**R&D expenses as a percentage of revenue:** 20% (2024)
**Patents and intellectual property:** Over 1000 patents (2024)
Genscript Biotech Corporation has a significant competitive advantage in the biotech industry, primarily supp...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** Approximately 45% (estimated for 2025 based on historical trends)
**Insider Purchases/Sales:** No specific data available for 2025, but historically moderate activity.
The institutional investor share in Genscript Biotech Corporation is estimated to be around 45%....
What percentage market share does Genscript Biotech have?
**Market share of Genscript Biotech:** Estimated 5-7% (2025)
**Top competitors and their market shares:**
1. Thermo Fisher Scientific: 15%
2. Merck KGaA: 12%
3. Danaher Corporation: 10%
4. Agilent Technologies: 8%
5. Bio-Rad Laboratories: 6%
6. Genscript Biotech: 5-7%
7. Qiagen: 4%
8. Illumina: 3%...
Is Genscript Biotech stock currently a good investment?
**Revenue Growth:** 18% (2024)
**Research and Development Expenses:** 20% of revenue (2024)
**Market Share in the Biotech Sector:** 5% (2024)
Genscript Biotech Corporation achieved a revenue growth of 18% in 2024, indicating strong demand for their biotechnological services and products. The compan...
Does Genscript Biotech pay a dividend – and how reliable is the payout?
**Dividend Yield:** 0.0% (2025)
Genscript Biotech Corporation has not paid any dividends in the past. The company focuses heavily on reinvesting its profits into research and development, as well as growing its business in the biotechnology sector.
The reliability of dividend payments is therefore...
